Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2201 - 2225 of 14935 in total
Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia for eye exams or ocular procedures. It is also used in combination with hydroxyamphetamine for the same indication. Oral tropicamide has...
Approved
Investigational
Matched Description: … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic ... [A230103] Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia …
Matched Categories: … Mydriatics and Cycloplegics …
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to...
Approved
Investigational
Matched Description: … the status of Fast Track, Priority Review and Orphan Drug designations. ... expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and ... [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the...
Approved
Matched Description: … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous...
Approved
Matched Description: … renal fluid reuptake by acting through V1 and V2 cellular receptors. ... [A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and ... hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and
Matched Categories: … Vasopressin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that ... erythematosus consists of antimalarials like [hydroxychloroquine], glucocorticoids like [dexamethasone], and ... placebo groups; and patient populations were largely homogenous, which may have increased the odds of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Approved
Matched Description: … A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. …
Matched Categories: … Antiglaucoma Preparations and Miotics ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Approved
Matched Categories: … Nucleic Acid Synthesis Inhibitors …
Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab...
Approved
Investigational
Matched Description: … works by inhibiting the inflammatory signaling pathway of IL-36,[L43090] which is often overexpressed and ... Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands ... , a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression ... Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
Approved
Matched Description: … A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical …
Matched Categories: … Antiseptics and Disinfectants …
A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Approved
Matched Description: … A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal...
Approved
Investigational
Withdrawn
Matched Description: … to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and ... was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Approved
Matched Description: … An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. …
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and ... [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission ... currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations...
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).[A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin. Anti-CD3 therapy...
Approved
Investigational
Matched Description: … L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and ... cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and ... mechanism of action of teplizumab has not been fully elucidated, it may involve partial agonistic signaling and
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Trials...
Approved
Investigational
Matched Description: … [L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 ( …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Anethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes , and even being used as an adjunctive therapy for cholecystitis,...
Approved
Experimental
Matched Description: … hepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. ... inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes [A32619], and ... even being used as an adjunctive therapy for cholecystitis, gallstone, indigestion, and acute/chronic …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and...
Approved
Investigational
Matched Description: … agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and ... [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for ... use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of...
Approved
Investigational
Matched Description: … promotes tumor cell lysis and apoptosis. ... monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and ... blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with DB13941 as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and...
Approved
Experimental
Investigational
Matched Description: … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated ... Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World …
Matched Categories: … Artemisinin and derivatives ... artenimol and piperaquine ... Antiparasitic Products, Insecticides and Repellents …
Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Approved
Experimental
Matched Description: … is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and
Matched Categories: … dihydralazine and diuretics ... Hydrazinophthalazine Derivatives and Diuretics ... dihydralazine and diuretics, combinations with other drugs …
Displaying drugs 2201 - 2225 of 14935 in total